BioNTech Historical Income Statement

BNTX Stock

USD 118.39 2.33 1.93%

Historical analysis of BioNTech income statement accounts such as Net Interest Income of 367.2 M, Interest Income of 375.5 M or Discontinued Operations of 0.0 can show how well BioNTech SE performed in making a profits. Evaluating BioNTech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioNTech's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining BioNTech SE latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNTech SE is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About BioNTech Income Statement Analysis

BioNTech SE Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioNTech shareholders. The income statement also shows BioNTech investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

BioNTech Income Statement Chart

At this time, BioNTech's Total Other Income Expense Net is fairly stable compared to the past year. Net Income Applicable To Common Shares is likely to rise to about 12.4 B in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.

Selling General Administrative Selling And Marketing Expenses Total Revenue Other Operating Expenses

Total Revenue

Total revenue comprises all receipts BioNTech SE generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioNTech SE. It is also known as BioNTech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from BioNTech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2021	2022	2023	2024 (projected)
Interest Expense	5.4M	18.9M	7.9M	7.5M
Depreciation And Amortization	78.2M	121.1M	183.4M	192.6M

Interest Expense Depreciation And Amortization

BioNTech income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense
Tax Provision		0.19	0.24	0.34	0.06	0.51	0.59	0.97	0.97	0.84	1.0	0.99	1.0	-0.12	1.0	0.96	-0.03	0.34	1.0	-0.06	0.99	1.0
Net Interest Income	0.19		1.0	0.93	0.1	0.92	0.86	0.42	0.41	0.66	0.21	0.28	0.23	0.79	0.24	0.34	0.84	0.94	0.25	0.97	0.28	0.19
Interest Income	0.24	1.0		0.94	0.11	0.94	0.88	0.47	0.46	0.7	0.26	0.32	0.27	0.79	0.28	0.38	0.83	0.95	0.3	0.95	0.32	0.24
Depreciation And Amortization	0.34	0.93	0.94		0.16	0.97	0.95	0.55	0.55	0.76	0.35	0.4	0.36	0.86	0.37	0.43	0.89	1.0	0.38	0.86	0.4	0.34
Interest Expense	0.06	0.1	0.11	0.16		0.19	0.18	0.12	0.09	0.18	0.1	0.11	0.09	0.22	0.09	0.23	-0.04	0.17	0.1	0.04	0.11	0.06
Selling General Administrative	0.51	0.92	0.94	0.97	0.19		0.99	0.7	0.7	0.87	0.52	0.57	0.53	0.74	0.54	0.6	0.78	0.97	0.55	0.81	0.57	0.51
Selling And Marketing Expenses	0.59	0.86	0.88	0.95	0.18	0.99		0.76	0.77	0.91	0.6	0.64	0.61	0.7	0.62	0.65	0.75	0.95	0.63	0.72	0.64	0.59
Total Revenue	0.97	0.42	0.47	0.55	0.12	0.7	0.76		1.0	0.93	0.97	0.98	0.97	0.1	0.98	0.97	0.18	0.55	0.98	0.18	0.98	0.97
Gross Profit	0.97	0.41	0.46	0.55	0.09	0.7	0.77	1.0		0.93	0.97	0.98	0.97	0.11	0.98	0.96	0.2	0.55	0.98	0.17	0.98	0.97
Other Operating Expenses	0.84	0.66	0.7	0.76	0.18	0.87	0.91	0.93	0.93		0.85	0.88	0.86	0.37	0.87	0.89	0.43	0.76	0.87	0.45	0.88	0.84
Operating Income	1.0	0.21	0.26	0.35	0.1	0.52	0.6	0.97	0.97	0.85		1.0	1.0	-0.12	1.0	0.97	-0.04	0.34	1.0	-0.04	1.0	1.0
Net Income From Continuing Ops	0.99	0.28	0.32	0.4	0.11	0.57	0.64	0.98	0.98	0.88	1.0		1.0	-0.08	1.0	0.99	0.0	0.39	1.0	0.03	1.0	0.99
Ebit	1.0	0.23	0.27	0.36	0.09	0.53	0.61	0.97	0.97	0.86	1.0	1.0		-0.11	1.0	0.97	-0.02	0.36	1.0	-0.02	1.0	1.0
Research Development	-0.12	0.79	0.79	0.86	0.22	0.74	0.7	0.1	0.11	0.37	-0.12	-0.08	-0.11		-0.1	-0.05	0.96	0.86	-0.09	0.83	-0.08	-0.12
Ebitda	1.0	0.24	0.28	0.37	0.09	0.54	0.62	0.98	0.98	0.87	1.0	1.0	1.0	-0.1		0.98	-0.01	0.37	1.0	-0.01	1.0	1.0
Cost Of Revenue	0.96	0.34	0.38	0.43	0.23	0.6	0.65	0.97	0.96	0.89	0.97	0.99	0.97	-0.05	0.98		0.0	0.43	0.98	0.09	0.99	0.96
Total Operating Expenses	-0.03	0.84	0.83	0.89	-0.04	0.78	0.75	0.18	0.2	0.43	-0.04	0.0	-0.02	0.96	-0.01	0.0		0.89	-0.01	0.86	0.0	-0.03
Reconciled Depreciation	0.34	0.94	0.95	1.0	0.17	0.97	0.95	0.55	0.55	0.76	0.34	0.39	0.36	0.86	0.37	0.43	0.89		0.38	0.87	0.39	0.34
Income Before Tax	1.0	0.25	0.3	0.38	0.1	0.55	0.63	0.98	0.98	0.87	1.0	1.0	1.0	-0.09	1.0	0.98	-0.01	0.38		0.0	1.0	1.0
Total Other Income Expense Net	-0.06	0.97	0.95	0.86	0.04	0.81	0.72	0.18	0.17	0.45	-0.04	0.03	-0.02	0.83	-0.01	0.09	0.86	0.87	0.0		0.03	-0.06
Net Income	0.99	0.28	0.32	0.4	0.11	0.57	0.64	0.98	0.98	0.88	1.0	1.0	1.0	-0.08	1.0	0.99	0.0	0.39	1.0	0.03		0.99
Income Tax Expense	1.0	0.19	0.24	0.34	0.06	0.51	0.59	0.97	0.97	0.84	1.0	0.99	1.0	-0.12	1.0	0.96	-0.03	0.34	1.0	-0.06	0.99

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	(268K)	(161M)	4.8B	3.5B	255.8M	243.0M
Net Interest Income	(263K)	(3.5M)	(25.8M)	311.4M	349.7M	367.2M
Interest Income	1.8M	1.6M	1.5M	330.3M	357.6M	375.5M
Depreciation And Amortization	35.4M	36.1M	78.2M	121.1M	183.4M	192.6M
Interest Expense	1.7M	64.9M	5.4M	18.9M	7.9M	7.5M
Selling General Administrative	40.7M	94.0M	278.5M	484.7M	495M	519.8M
Selling And Marketing Expenses	2.7M	14.5M	50.4M	59.5M	62.7M	65.8M
Total Revenue	108.6M	482.3M	19.0B	17.3B	3.8B	6.4B
Gross Profit	(135.2M)	(222.0M)	15.1B	12.8B	3.2B	4.8B
Other Operating Expenses	290.1M	564.7M	4.1B	4.7B	3.1B	2.0B
Operating Income	(181.5M)	(82.4M)	15.3B	12.6B	690.4M	655.9M
Net Income From Continuing Ops	(179.2M)	15.2M	10.3B	9.4B	930.3M	883.8M
Ebit	(181.5M)	(141.2M)	14.9B	12.3B	904.2M	859.0M
Research Development	226.5M	645.0M	102.7M	116M	1.8B	1.9B
Ebitda	(146.2M)	(105.1M)	15.0B	12.4B	1.1B	1.0B
Cost Of Revenue	243.8M	704.4M	3.9B	4.5B	599.8M	569.8M
Total Operating Expenses	46.3M	(139.6M)	200.1M	135.9M	2.5B	2.7B
Reconciled Depreciation	33.9M	38.7M	75.2M	123.3M	183.4M	192.6M
Income Before Tax	(179.4M)	(145.8M)	15.0B	13.0B	1.2B	1.1B
Total Other Income Expense Net	2.1M	(63.4M)	(237.4M)	311.4M	495.7M	520.5M
Net Income Applicable To Common Shares	(48.0M)	(179.1M)	15.2M	10.3B	11.8B	12.4B
Net Income	(179.2M)	15.2M	10.3B	9.4B	930.3M	883.8M
Income Tax Expense	(268K)	(161M)	4.8B	3.5B	255.8M	243.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Historical Income Statement

About BioNTech Income Statement Analysis

BioNTech Income Statement Chart

Total Revenue

Other Operating Expenses

BioNTech income statement Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech income statement Accounts

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Operating Income	+ 1.0	Tax Provision
Ebit	+ 1.0	Tax Provision
Ebitda	+ 1.0	Tax Provision
Income Before Tax	+ 1.0	Tax Provision
Income Tax Expense	+ 1.0	Tax Provision
Interest Income	+ 1.0	Net Interest Income

Income Tax Expense	- 0.12	Research Development
Research Development	- 0.12	Operating Income
Research Development	- 0.12	Tax Provision
Research Development	- 0.11	Ebit
Ebitda	- 0.1	Research Development
Income Before Tax	- 0.09	Research Development